OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
DYAI$0.7859

Dyadic International Inc

Biotechnology & Medical ResearchVerified

Dyadic International Inc has a market capitalization of $28.6 million and a price-to-book ratio of 23.2, indicating a high valuation relative to its book value. The company's liquidity position is characterized by $4.6 million in cash and equivalents, but it also carries $5.0 million in long-term debt, resulting in a debt-to-equity ratio of 4.08. The current ratio of 2.68 suggests the company has sufficient current assets to cover its current liabilities. The company's profitability is weak, with a net loss of $7.4 million and an operating loss of $7.2 million in the latest reporting period. Return on equity is negative at -5.98%, and return on assets is also negative at -0.74%, indicating poor capital efficiency and asset utilization. The company's gross profit of $770,490 is significantly lower than its operating and net losses, highlighting the challenges in converting revenue into profit. Dyadic International Inc operates in a single business segment, and its geographic exposure is not disclosed in the available data. The company's revenue concentration is not specified, but the lack of segment or geographic breakdown suggests a relatively undiversified business model. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The operating cash flow is negative at -$5.7 million, indicating that the company is not generating sufficient cash from operations to sustain its activities. The company's financial performance and cash flow position suggest a need for external financing or operational improvements to achieve sustainable growth. The risk assessment for Dyadic International Inc indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term, which is a positive sign for existing shareholders. Recent events and disclosures for Dyadic International Inc include analyst price targets ranging from $5.00 to $7.00, with a mean and median price target of $6.00. The mean recommendation from analysts is 2.00, indicating a "buy" rating, with one analyst issuing a "buy" recommendation and none issuing a "strong buy" or "hold". These analyst estimates suggest a generally positive outlook, but the lack of strong buy ratings indicates some caution among analysts.

30-day price · DYAI(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyDyadic International Inc
TickerDYAI.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Dyadic International Inc is a biotechnology company focused on the development and commercialization of diagnostic and therapeutic products for the healthcare industry.

Classification. Dyadic International Inc is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

Dyadic International Inc has a market capitalization of $28.6 million and a price-to-book ratio of 23.2, indicating a high valuation relative to its book value. The company's liquidity position is characterized by $4.6 million in cash and equivalents, but it also carries $5.0 million in long-term debt, resulting in a debt-to-equity ratio of 4.08. The current ratio of 2.68 suggests the company has sufficient current assets to cover its current liabilities. The company's profitability is weak, with a net loss of $7.4 million and an operating loss of $7.2 million in the latest reporting period. Return on equity is negative at -5.98%, and return on assets is also negative at -0.74%, indicating poor capital efficiency and asset utilization. The company's gross profit of $770,490 is significantly lower than its operating and net losses, highlighting the challenges in converting revenue into profit. Dyadic International Inc operates in a single business segment, and its geographic exposure is not disclosed in the available data. The company's revenue concentration is not specified, but the lack of segment or geographic breakdown suggests a relatively undiversified business model. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The operating cash flow is negative at -$5.7 million, indicating that the company is not generating sufficient cash from operations to sustain its activities. The company's financial performance and cash flow position suggest a need for external financing or operational improvements to achieve sustainable growth. The risk assessment for Dyadic International Inc indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term, which is a positive sign for existing shareholders. Recent events and disclosures for Dyadic International Inc include analyst price targets ranging from $5.00 to $7.00, with a mean and median price target of $6.00. The mean recommendation from analysts is 2.00, indicating a "buy" rating, with one analyst issuing a "buy" recommendation and none issuing a "strong buy" or "hold". These analyst estimates suggest a generally positive outlook, but the lack of strong buy ratings indicates some caution among analysts.
Key takeaways
  • Dyadic International Inc has a high price-to-book ratio of 23.2, indicating a premium valuation relative to its book value.
  • The company is currently unprofitable, with a net loss of $7.4 million and an operating loss of $7.2 million.
  • The company's liquidity position is mixed, with $4.6 million in cash and equivalents but a debt-to-equity ratio of 4.08.
  • Analysts have a generally positive outlook, with a mean price target of $6.00 and a "buy" recommendation.
  • The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$3.1M
Gross profit$770.5k
Operating income-$7.2M
Net income-$7.4M
R&D
SG&A
D&A
SBC
Operating cash flow-$5.7M
CapEx
Free cash flow
Total assets$9.9M
Total liabilities$8.7M
Total equity$1.2M
Cash & equivalents$4.6M
Long-term debt$5.0M
Valuation
Market price$0.78
Market cap$28.6M
Enterprise value$29.0M
P/E
Reported non-GAAP P/E
EV/Revenue9.4
EV/Op income
EV/OCF
P/B23.2
P/Tangible book23.2
Tangible book$1.2M
Net cash-$403.7k
Current ratio2.7
Debt/Equity4.1
ROA-74.1%
ROE-6.0%
Cash conversion77.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricDYAIActivity
Op margin-232.8%-227.5% medp25 -1250.6% · p75 -3.5%below median
Net margin-238.3%-194.5% medp25 -1233.8% · p75 0.8%below median
Gross margin24.9%53.0% medp25 25.9% · p75 75.7%bottom quartile
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity408.0%1.2% medp25 0.0% · p75 17.4%top quartile
Observations
IR observations
Mean price target6.00 USD
Median price target6.00 USD
High price target7.00 USD
Low price target5.00 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.09 USD
Last actual EPS-0.23 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 22:45 UTC#0067ea7b
Market quoteclose USD 0.78 · shares 0.04B diluted
no public URL
2026-05-08 13:34 UTC#67188c36
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 19:40 UTCJob: 0b74a540